On October 23, 2018 at 8:00 PM EDT: Dr. Aron Tendler, chief medical officer at BrainsWay, will host the webinar, “Deep TMS: Transforming the Treatment Paradigm for OCD.” This webinar will introduce BrainsWay’s platform TMS system, which was recently FDA approved for the treatment of treatment-resistant OCD. During the webinar, Dr. Tendler will discuss OCD including how it is diagnosed and treated. He will also speak about brain stimulation as a new treatment option for use in treatment-resistant patients and the company’s deep TMS device, which has the potential to transform the current standard of care for OCD.
About OCD: Over 1.2 million OCD patients are considered treatment resistant to first-line therapies, including SSRIs. After first-line therapies fail, many physicians consider neuromodulation options such as brain surgery. A new, non-invasive neuromodulation strategy involves TMS targeting the anterior cingulate cortex region of the brain. In addition to providing another treatment option for patients and improving patient quality of life, TMS may also be more cost effective for patients.
About TMS: Deep brain stimulation works to target specific areas of the brain and can affect the treatment of certain disorders including OCD and depression. Brain stimulation devices utilizing transcranial magnetic stimulation (TMS) technology have also recently been approved to treat disorders including OCD and depression.